Pathology studies have also demonstrated that demyelinating cortical lesions and cortical neurodegeneration occur in early stages of MS with nearly 40% of individuals undergoing brain biopsy showing cortical demyelination. 4 Cortical atrophy also has been demonstrated at the time of disease onset using imaging studies. An MR study comparing RRMS and primary progressive multiple sclerosis (PPMS) patients showed that cortical volume loss not only occurs early but is also significantly associated with neurological impairment and may occur in the setting of minimal white matter lesion accumulation. 5 Pathological examination of the spinal cord also demonstrates that neuronal loss occurs in the presence of gray matter and anterior horn demyelination, but not as a function of age. 6 Several studies have shown that baseline and early T2 lesion volume accumulation correlate with long-term disability outcomes independent of age. T2 lesion volume in early RRMS predicts brain atrophy and clinical disease severity over time. Although age and disease duration are associated with greater lesion accumulation, available data suggest that focal lesion accumulation rather than age itself is the primary driver of disease progression. Longitudinal studies have also assessed the predictive value of baseline gray matter damage in MS on long-term disability and cognitive impairment. Baseline gray matter fraction was a significant predictor of worsening disability, while age was not. Similarly, in PPMS, significant predictors of 15-year disability included baseline EDSS, baseline gray matter diffusivity, new T1 lesions, and percent change in brain volume loss, but not age. 7 The evidence that baseline T2 lesions and gray matter damage predict long-term disability suggests that early changes are drivers of progression later in the disease course.
Perhaps the best evidence that disease progression is not an age-dependent phenomenon comes from pediatric MS studies, which have demonstrated significant MR progression despite short duration and younger age. A study of 28 pediatric MS patients found significant loss of thalamic volume compared to controls, and it also appears there is a failure of age-expected brain growth both in the thalamus and in the whole brain volume. 8 Demyelination of the cerebral cortex, though to be a marker of progressive disease, has been found in pediatric MS. In addition to pediatric MS, evidence of progression has been documented in radiologically isolated syndrome (RIS), the earliest stage of MS. In RIS, thalamic volume is significantly smaller when compared to healthy controls. 9 Changes in spinal cord microstructure, including magnetization transfer, have also been documented in RIS patients when compared to healthy controls. 10 Studies from pediatric MS and RIS demonstrate progressive tissue changes with short disease duration and in groups with lower ages.
Extensive evidence from pathology, imaging studies, and early disease onset studies support the hypothesis that neurodegeneration occurs from the very onset of disease, is associated with early lesion accumulation, and occurs independent of age producing significant impact on the long-term clinical progression seen in MS. Although age may accelerate the process of progression, available data suggest that degeneration in the brain and spinal cord may occur independently of disease course and age. Refining our ability to capture progression, for example, using technology-enabled measures, may reveal progressive deterioration of clinical function more sensitively and earlier in the disease course. The possibility that degeneration occurs early highlights the need for early institution of effective disease-modifying agents to prevent longterm disability.
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The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. In MS, while the frequency of relapses decreases with aging, recovery from relapses also decreases. 1 Since spontaneous recovery is more evident in younger individuals, not surprisingly a positive impact on recovery is easier to detect in patients older than the third decade. 2 As compact white matter myelination terminates by the fourth decade, ensuing insidious white matter integrity loss 3 likely leads to impairment of white matter reserve. A gradual switch from active to inactive plaques and a "rise" in the smoldering plaques are observed in the fifth decade. 4 Smoldering plaques and enlarging lesions are hallmarks of progressive MS. Mean age at clinical onset of progressive MS is also in the fifth decade. 5 Clinical progressive phase of MS is preprogression agnostic with seemingly no impact of density of relapses on the age at onset of progressive phase. In many patients, imaging findings during the asymptomatic phase of radiologically isolated syndrome (RIS) preceding primary progressive multiple sclerosis (PPMS) 6 are indistinguishable from imaging findings during the relapsing-remitting phase preceding secondary progressive multiple sclerosis (SPMS). However, a poor recovery from early
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